Strand V, Tundia N, Song IH, et al. Early patient-reported outcomes and clinical outcomes with ABT-494 in patients with active rheumatoid arthritis who are inadequate responders to methotrexate or tumor necrosis factor inhibitors: post-hoc analysis of phase 2 randomized controlled trials. EULAR 2017, SAT0217.
MUC5B-promotervariant rs35705950 risicofactor voor RA-geassocieerde ILD
jan 2019 | ILD, RA